정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1717 | Recruiting | Dietary Supplements Vit D, Quercetin and Curcumin Combination for Early Symptoms of COVID-19 | Covid19 | Drug: Standard of care Dietary Supplement: combination of curcumin, quercetin and Vitamin D |
Not Applicable | Ayub Teaching Hospital | OTHER | 100 | All | 18 Years | Ayub Teaching Hospital, Abbottabad, Khyber Pakhtunkhwa, Pakistan |
| 1716 | Completed | Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 | Covid19 | Drug: Linagliptin tablet Drug: Insulin |
Phase 3 | Hospital Regional de Alta Especialidad del Bajio | OTHER | 70 | All | 18 Years ~ 75 Years | Hospital Regional de Alta Especialidad del Bajio, Leon, Guanajuato, Mexico |
| 1715 | Completed | Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | SARS-CoV-2 Infection | Drug: Dipyridamole 100 Milligram(mg) Drug: Placebo oral tablet |
Phase 2 | University of Michigan | OTHER | 100 | All | 18 Years | University of Michigan, Ann Arbor, Michigan, United States |
| 1714 | Not yet recruiting | Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome | ARDS, Human | Drug: Instilled T3 Other: Placebo Therapy |
Phase 2 | University of Minnesota | OTHER | 250 | All | 18 Years ~ 80 Years | University of Minnesota, Minneapolis, Minnesota, United States |
| 1713 | Active, not recruiting | Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) | Covid19 | Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection | Early Phase 1 | Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair | INDUSTRY | 20 | All | 22 Years ~ 72 Years | Medicine Invention Design, Inc. (MIDI) - c/o - MIDINC Clinical Investigator Working Site, North Bethesda, Maryland, United States |
| 1712 | Recruiting | DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1) | COVID-19 Infection | Drug: rhDNase I | Phase 1 | McGill University Health Centre/Research Institute of the McGill University Health Centre, Hamilton Health Sciences Corporation, Hoffmann-La Roche, Exactis Innovation | OTHER | 25 | All | 18 Years | Hamilton General Hospital, Hamilton Health Sciences, Hamilton, Ontario, Canada McGill University Health Centre, Montreal, Quebec, Canada |
| 1711 | Recruiting | DISulfiram for COvid-19 (DISCO) Trial | Covid19 | Drug: Disulfiram Drug: Placebo |
Phase 2 | University of California, San Francisco | OTHER | 60 | All | 18 Years | University of California San Francisco, Fresno, Fresno, California, United States San Francisco General Hospital, San Francisco, California, United States |